Skip to main navigation
Skip to main content

Utility Nav Header

  • Contact
  • Twitter
  • LinkedIn

Main navigation

  • About
    • Our Focus
    • CEO Video
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Corporate Responsibility
      • Corporate Governance
      • Diversity & Inclusion
      • Corporate Giving
  • Our Science
    • Our Approach
    • Pipeline
      • Pipeline
      • Repotrectinib
      • Elzovantinib (TPX-0022)
      • TPX-0046
      • TPX-0131
    • Publications & Presentations
  • Clinical Trials
    • Company Trials
    • Compassionate Use
    • Investigator Sponsored Research
  • Investors
    • Overview
    • Press Releases
    • Events
    • Presentations
    • SEC Filings
    • Quarterly Results
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Leadership
      • Committee Composition
    • Investor Contact
    • Email Alerts
  • Careers
    • Vision, Mission & Values
    • Our Culture
    • Diversity & Inclusion
    • Opportunities
    • Our Hiring Process
    • Benefits

Press Releases

Turning Point Therapeutics to Participate in 42nd Annual Cowen Healthcare Conference

Mar 01, 2022

Turning Point Therapeutics Reports Fourth-Quarter and Full Year 2021 Financial Results, Provides Operational Updates

Feb 28, 2022

Turning Point Therapeutics to Participate in Upcoming Investor Conferences

Feb 02, 2022

Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for Combination of Elzovantinib and Aumolertinib in EGFR Mutant Met-Amplified Non-Small Cell Lung Cancer

Jan 20, 2022

Turning Point Therapeutics Provides Updates and Anticipated 2022 Clinical and Discovery Pipeline Milestones

Jan 18, 2022

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
Copyright © 2022 Turning Point Therapeutics, Inc. | All Rights Reserved | Sitemap | Terms of Use | Privacy Policy Statement